



## Disease Modifying Therapies for the Treatment of Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM): Effectiveness and Value

Friday • September 20, 2024 • 10:00 AM – 4:00 PM CT

Virtual Event – Zoom Webinar

Time (CT)	Activity
<b>10:00 AM – 10:20 AM</b>	<b>Meeting Convened and Opening Remarks</b> Sarah K. Emond, MPP President and CEO, ICER  Steven D. Pearson, MD, MSc Special Advisor, ICER
<b>10:20 AM – 11:00 AM</b>	<b>Presentation of the Clinical Evidence</b> Jason H. Wasfy, MD, MPhil Associate Professor, Harvard Medical School Director of Outcomes Research and Cardiologist, Massachusetts General Hospital Heart Center
<b>11:00 AM – 11:40 AM</b>	<b>Presentation of the Economic Model</b> Aaron, Winn, MPP, PhD Associate Professor, University of Illinois at Chicago
<b>11:40 AM – 12:00 PM</b>	<b>Public Comments and Discussion</b>
<b>12:00 PM – 12:50 PM</b>	<b>Lunch Break</b>
<b>12:50 PM – 1:50 PM</b>	<b>Midwest CEPAC Vote on Clinical Effectiveness and Value</b>
<b>1:50 PM – 2:00 PM</b>	<b>Break</b>
<b>2:00 PM – 3:30 PM</b>	<b>Policy Roundtable</b>
<b>3:30 PM – 4:00 PM</b>	<b>Reflections from Midwest CEPAC</b>
<b>4:00 PM</b>	<b>Meeting Adjourned</b>